Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro
- PMID: 23601711
- DOI: 10.1016/j.bmcl.2013.03.097
Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro
Abstract
The small chemical compound 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161) was recently identified as an inhibitor of the phosphoinositide 3-kinase (PI3K). In the present study, we designed a novel synthesis of S14161 and prepared a series of its analogues via the oxa-Michael-Henry reaction in the presence of catalytic amounts of l-proline and triethylamine. Further structural simplification led to the identification of 6-bromo-8-ethoxy-3-nitro-2H-chromene (BENC-511) that exhibited potent antiproliferative activities against a panel of 12 tumor cell lines. Compared with S14161, BENC-511 was more potent in blocking the AKT phosphorylation and inducing cancer cell apoptosis. BENC-511 also displayed more potent effects on human umbilical vein epithelial cells (HUVEC) migration, suggesting its anti-angiogenesis activity.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.J Hematol Oncol. 2014 Jan 15;7:9. doi: 10.1186/1756-8722-7-9. J Hematol Oncol. 2014. PMID: 24428908 Free PMC article.
-
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.Biosci Trends. 2019;13(1):40-48. doi: 10.5582/bst.2019.01006. Biosci Trends. 2019. PMID: 30867372
-
Synthesis of sulfonylhydrazone- and acylhydrazone-substituted 8-ethoxy-3-nitro-2H-chromenes as potent antiproliferative and apoptosis inducing agents.Arch Pharm (Weinheim). 2014 Aug;347(8):576-88. doi: 10.1002/ardp.201400082. Epub 2014 May 27. Arch Pharm (Weinheim). 2014. PMID: 24866448
-
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.Blood. 2011 Feb 10;117(6):1986-97. doi: 10.1182/blood-2010-05-284810. Epub 2010 Dec 6. Blood. 2011. PMID: 21135258
-
Chromenes: potential new chemotherapeutic agents for cancer.Future Med Chem. 2013 Sep;5(14):1647-60. doi: 10.4155/fmc.13.126. Future Med Chem. 2013. PMID: 24047270 Review.
Cited by
-
Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161.PLoS One. 2014 Aug 12;9(8):e102394. doi: 10.1371/journal.pone.0102394. eCollection 2014. PLoS One. 2014. PMID: 25115838 Free PMC article.
-
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.J Hematol Oncol. 2014 Jan 15;7:9. doi: 10.1186/1756-8722-7-9. J Hematol Oncol. 2014. PMID: 24428908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources